AstraZeneca stock rises on progress with breast cancer treatment

Shares of AstraZeneca (AZN) rose in a sharply down market after the British drugmaker reported progress with a breast-cancer drug candidate.
Enhertu reduced disease progression or death by 72 per cent vs. a currently approved treatment, the company said…

Click here to view the original article.